Article thumbnail

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

By Christine R Swanson, Valerie Joers, Viktoriya Bondarenko, Kevin Brunner, Heather A Simmons, Toni E Ziegler, Joseph W Kemnitz, Jeffrey A Johnson and Marina E Emborg
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3166925
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A call for clinically driven experimental design in assessing neuroprotection in experimentla Parkinsonism. Behavioral Pharmacology
  2. (2006). Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-suceptible EL mice. Brain Res
  3. (2008). Beal MF: PPAR: a therapeutic target in Parkinson’s disease.
  4. (1992). Colca JR: Treatment of insulinresistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology
  5. (2002). DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
  6. (2005). Dello Russo C: Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol
  7. (2009). DL: A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
  8. (1998). Domino EF: MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Exp Neurol
  9. (2002). EC: Protective action of the peroxisome proliferator-activated receptorgamma agonist pioglitazone in a mouse model of Parkinson’s disease.
  10. (2002). EJ: Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res
  11. (2009). Emborg ME: Can we prevent parkinson’s disease? Front Biosci
  12. (2008). Emborg ME: Contributions of non-human primates to neuroscience research. Lancet
  13. (2010). Emborg ME: Research ethics. Beyond access vs. protection in trials of innovative therapies. Science
  14. (1996). Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method.
  15. (2006). et al: Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis
  16. (2000). et al: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science
  17. (1998). et al: Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose updtake in noninsulin dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract
  18. (2009). et al: Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis
  19. (2004). Evaluation of animal models of Parkinson’s disease for neuroprotective strategies.
  20. (2007). Feinstein DL: Effect of pioglitazone treatment on behavioral symptoms in autistic children.
  21. (2010). Feinstein DL: Effects of pioglitazone on diffusion tensor imaging indicies in multiple sclerosis patients. Neurosci Lett
  22. (2009). Fitzer-Attas CJ: Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson’s Disease. Movement Disorders
  23. (1990). Fujita T: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung
  24. (2011). G: A randomized pilot clinical trial of the safety of piogltiazone in treatment of patients with Alzheimer disease. Arch Neurol
  25. (2005). GE: Acute treatment with the PPARgamma agonist piogltiazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV7171. Brain
  26. (2002). Heneka MT: Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol
  27. (2005). Heneka MT: The oral antidiabetic pioglitazone protects from neurodegenerative and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.
  28. (2004). Herrero MT: Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 years after MPTP exposure. Glia
  29. (2010). Hong JS: Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy.
  30. (2009). Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol
  31. (2007). Inflammation induces mitochondirial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
  32. Insulin Resistance Intervention after Stroke.
  33. Iwamoto T: Efficacy of PPAR-gama agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging .
  34. (1997). Jagust WJ: PET studies of functional compensation in a primate modle of Parkinson’s disease. NeuroReport
  35. (2004). JB: Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NFkappa B and iNOS activation.
  36. (2007). Kim-Mitsuyama S: Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke
  37. (1998). Kordower JH: Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys.
  38. (2000). MR: Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther
  39. (2007). Nonhuman primate models of Parkinson’s disease.
  40. (1991). Pakkenberg H: The absolutely number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method.
  41. (2008). Physician’s Desk Reference. 64 edition.
  42. (1994). Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes
  43. (2007). PJ: A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for Swanson et al.
  44. (2003). Presence of Reactive Microglia in Monkey Substantia Nigra Years after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Administration. Ann Neurol
  45. (2008). Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett
  46. (2006). Realistic expectations for treatment success in Alzheimer’s disease.
  47. (2006). Saraphanchotiwitthaya A: High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study.
  48. (1986). Schmuff NR: The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev
  49. (1988). Sokoloff L: Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res
  50. (1985). SP: Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci
  51. (1988). SP: Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin. Chem Res Toxicol
  52. Tansey MJ: Modeling neuroinflammatory pathogenesis of Parkinson’s disease.
  53. (2011). Tarelli R: Parkinson’s disease and systemic inflammation. Parkinsons Dis
  54. (2007). Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther
  55. (2008). Virley DJ: The PPAR-gamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. Br J Pharmacol
  56. (2005). Youdim MB: Mechanisms of neuroprotective actions of the anti-Parkinsonian drug resagilline and its derivitives. Brain Research Reviews
  57. (2010). Zhang HL: Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferatoractivated receptor gamma-mediated suppression of nuclear factor kappa-B signaling pathway. Neuroscience